- Switzerland-based BioCopy AG has collaborated with Immatics N.V. IMTX to characterize T cell receptors (TCRs).
- T cell receptors and their interactions with peptide-HLA complexes (human leukocyte antigen) play a crucial role for the human immune system in recognition of tumors, among other things.
- BioCopy's technology enables high-throughput screening of T cell receptors for binding to a wide variety of peptide-HLA complexes, thus contributing a safety screening for novel TCR-based cancer cell therapies.
- This collaboration aims to enable the characterization of more than 5,000 different TCR-peptide-HLA interactions simultaneously to accelerate the development of T-cell-based cancer therapies by facilitating large pre-clinical safety screenings.
- Price Action: IMTX shares are down 0.34% at $11.75 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
